Form 4: Carlyle Group Sells Additional Shares of QuidelOrtho Corp (QDEL) Under 10b5-1 Plan

Carlyle Group Inc. reports the sale of QuidelOrtho Corp shares across multiple transactions on August 5th and 6th, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Carlyle Group Inc. and related entities have reported the sale of common stock in QuidelOrtho Corp (QDEL) on August 5th and 6th, 2024.
• The sales were executed under a Rule 10b5-1 trading plan adopted on May 12, 2024.
• On August 5th, a total of 118,172 shares were sold at weighted average prices ranging from $38.97 to $41.1703.
• On August 6th, a total of 86,972 shares were sold at weighted average prices ranging from $39.45 to $40.97.
• Following these transactions, Carlyle Partners VI Cayman Holdings, L.P. beneficially owns 8,519,202 shares of QuidelOrtho Corp.
• The Carlyle Group Inc. disclaims beneficial ownership of these securities.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a routine disclosure of share sales under a pre-existing plan. No indication of positive or negative outlook.

Risks

• Continued sales by Carlyle Group could exert downward pressure on QuidelOrtho's stock price.

Future Outlook

The document does not contain any specific forward-looking statements regarding QuidelOrtho's future performance.

Industry Context

This filing reflects ongoing transactions by a major shareholder, which is a common occurrence. The impact on QuidelOrtho will depend on market perception and the overall health of the diagnostics industry.

Stakeholder Impact

• The share sales could potentially impact shareholder value if perceived negatively by the market.

Key Dates